我们进行了一项多中心研究，分析了近期接受异基因造血干细胞移植（allo-HSCT）治疗的TP53基因突变（m）AML患者存活预测因素。370名TP53m AML患者中，有68名（18％）患者桥接了allo-HSCT。患者的中位年龄为63岁（范围为33-75岁），82％的患者存在复杂细胞遗传学，66％的患者具有多个TP53m。43％接受了髓毒性条件化，57％接受了减轻强度条件化。急性移植物抗宿主病（GVHD）的发生率为37％，慢性GVHD的发生率为44％。从allo-HSCT开始的中位无事件生存期（EFS）为12.4个月（95％CI：6.24-18.55），中位总生存期（OS）为24.5个月（95％CI：21.80-27.25）。在使用单变量分析显示显著性的变量进行多元分析时，allo-HSCT后100天的完全缓解保持了EFS（HR：0.24，95％CI：0.10-0.57，p = 0.001）和OS（HR：0.22，95％CI：0.10-0.50，p ≤ 0.001）的显著性。同样，慢性GVHD的发生对EFS（HR：0.21，95％CI：0.09-0.46，p≤0.001）和OS（HR：0.34，95％CI：0.15-0.75，p = 0.007）的显著性保持不变。我们的报告表明allo-HSCT为TP53m AML患者提供了最佳机会，以改善长期疗效。 ©2023年作者（以独家许可证授予Springer Nature Limited）。

We conducted a multi-center study to analyze factors predicting survival among patients with TP53-mutated (m) AML receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. Out of 370 TP53m AML patients, 68 (18%) patients were bridged to allo-HSCT. The median age of the patients was 63 years (range, 33-75), 82% of patients had complex cytogenetics and 66% of patients had multi-hit TP53m. Forty three percent received myeloablative conditioning and 57% received reduced intensity conditioning. The incidence of acute graft versus host disease (GVHD) was 37% and chronic GVHD was 44%. The median event-free survival (EFS) from the time of allo-HSCT was 12.4 months (95% CI: 6.24-18.55) and median overall survival (OS) was 24.5 months (95% CI: 21.80-27.25). In multivariate analysis utilizing variables that showed significance in univariate analysis, complete remission at day 100 post allo-HSCT retained significance for EFS (HR: 0.24, 95% CI: 0.10-0.57, p = 0.001) and OS (HR: 0.22, 95% CI: 0.10-0.50, p ≤ 0.001). Similarly, occurrence of chronic GVHD retained significance for EFS (HR: 0.21, 95% CI: 0.09-0.46, p ≤ 0.001) and OS (HR: 0.34, 95% CI: 0.15-0.75, p = 0.007). Our report suggests that allo-HSCT offers the best opportunity to improve long-term outcome among patients with TP53m AML.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.